Drug Trial Radar · NCT07640984
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Jun 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- MEDIPAL HOLDINGS CORPORATION
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early clinical effects on disease-relevant outcomes.
Conditions
- Mucopolysaccharidosis IIIB
Interventions
JR-446Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To establish the safety and tolerability of JR-446 in MPS IIIB patients following repeated dose administrationTime frame: Up to 1 year (multiple visits)
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital Oakland Research Institution, Attn: 2900 Wing
Oakland, California · Recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Not yet recruiting
Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)
Fairfax, Virginia · Not yet recruiting
University Medical Center Hamburg-Eppendorf
Hamburg, Germany · Not yet recruiting
Great Ormond Street Hospital for Children
London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.